Daliresp Will Be Sold in Pill Form to Treat Chronic Obstructive Pulmonary Disease March 1, 2011 -- The FDA has approved a new treatment for people with worsening symptoms of severe chronic obstructive pulmonary disease (COPD), a lung disorder that makes breathing difficult. The drug, roflumilast -- carrying the trade name Daliresp -- will be sold in pill form, unlike some other medications for COPD, which are inhaled. The FDA says roflumilast, a new drug class for COPD treatment, is an inhibitor of an enzyme called phosphodiesterase type 4 (PDE-4). The pill is recommended for people with severe COPD to treat symptoms of cough and excess mucus linked to bronchitis. It is not intended to treat another form of COPD, which involves primary emphysema. The FDA's approval was announced even though the agency's advisory panel voted 10-5 on April 7, 2010, not to recommend approval of the once-daily pill. At the time the panel members decided the drug had too many adverse effect...